Falco Holdings CoTSE:4671 -0.39%71 EBITDA Margin % is 3.62% as of Dec. 2025, which is 57% below its 10-year median of 8.44. GuruFocus rates TSE:4671 with a GF Score™ of 71/100 and a GF Value™ of 円2,528.99 (Fairly Valued). The stock has 6 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Falco Holdings Co ranks better than 56.86% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Falco Holdings Co's EBITDA for the
three
months ended in Dec. 2025 was 円403 Mil. Falco Holdings Co's Revenue for the
three
months ended in Dec. 2025 was 円11,145 Mil. Therefore, Falco Holdings Co's EBITDA margin for the quarter that ended in Dec. 2025 was 3.62%.
Falco Holdings Co (TSE:4671) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Falco Holdings Co EBITDA Margin % Related Terms
Falco Holdings Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Falco Holdings Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4671 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Falco Holdings Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Falco Holdings Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Falco Holdings Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Falco Holdings Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Falco Holdings Co (TSE:4671) has a EBITDA Margin % of 3.62% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Falco Holdings Co and its competitors. This is 57% below median its historical median of 8.44. Over the past decade, Falco Holdings Co's EBITDA Margin % has ranged from 4.62 to 13.10. According to the industry distribution chart, Falco Holdings Co ranks #88 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 43.1%.
Is Falco Holdings Co's EBITDA Margin % too high?
Falco Holdings Co's current EBITDA Margin % of 3.62% is 57% below median its 10-year median of 8.44. Over the past 10 years, this metric has ranged from a low of 4.62 to a high of 13.10. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Falco Holdings Co's value of 3.62% is 30.4% below this industry median. Based on the distribution chart, Falco Holdings Co ranks #88 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Falco Holdings Co has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Falco Holdings Co's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Falco Holdings Co ranks #88 out of 204 companies for EBITDA Margin %. This puts Falco Holdings Co in the upper half of its industry. The industry median EBITDA Margin % is 5.20. Falco Holdings Co's value of 3.62% is 30.4% below this benchmark. Historically, Falco Holdings Co's own EBITDA Margin % has ranged from 4.62 to 13.10 over the past decade. While the company's 10-year median is 8.44 vs. the industry median of 5.20, Falco Holdings Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Falco Holdings Co's current EBITDA Margin % of 3.62% is 30.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Falco Holdings Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Falco Holdings Co's current EBITDA Margin % is 3.62%, which is 57% below median its own 10-year median of 8.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Falco Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Falco Holdings Co (TSE:4671) is currently considered Fairly Valued. The stock's GF Value™ is 円2,528.99, compared to a current price of 円2,544.00 — trading 0.6% above its estimated fair value. The current EBITDA Margin % is 3.62%, which is 57% below median its 10-year median of 8.44 and 30.4% below the Medical Diagnostics & Research industry median of 5.20. Falco Holdings Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Falco Holdings Co (TSE:4671), the current EBITDA Margin % is 3.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Falco Holdings Co (TSE:4671) Overvalued in 2026?
Based on GuruFocus' analysis, Falco Holdings Co stock appears to be overvalued.
The current stock price of 円2,544.00 is trading 0.6% above its estimated GF Value™ of 円2,528.99.
GuruFocus considers Falco Holdings Co to be Fairly Valued.
Key valuation signals for TSE:4671:
EBITDA Margin %: 3.62% (57% below median its 10-year median of 8.44)
GF Value™: 円2,528.99 vs. price of 円2,544.00 (0.6% above fair value)
Industry Position: 30.4% below the Medical Diagnostics & Research median (#88 of 204)
No single metric tells the full story. See the TSE:4671 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Falco Holdings Co Ltd provides testing services. The company is engaged in providing clinical testing and genetic testing services, testing in clinical research and clinical trials, food sanitation, and environmental testing, and pharmacy business. It also engaged in providing information technology business.
71GF Score
Get the complete analysis for TSE:4671
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4671 has been successfully added to your 
